Myeloperoxidase Alters Lung Cancer Cell Function to Benefit Their Survival

Research output: Contribution to journalJournal articleResearchpeer-review


  • Fulltext

    Final published version, 4.4 MB, PDF document

  • Nejra Cosic-Mujkanovic
  • Paulina Valadez-Cosmes
  • Kathrin Maitz
  • Anna Lueger
  • Zala N. Mihalic
  • Marah C. Runtsch
  • Melanie Kienzl
  • Davies, Michael J.
  • Chuang, Christine
  • Akos Heinemann
  • Rudolf Schicho
  • Gunther Marsche
  • Julia Kargl

Myeloperoxidase (MPO) is a neutrophil-derived enzyme that has been recently associated with tumour development. However, the mechanisms by which this enzyme exerts its functions remain unclear. In this study, we investigated whether myeloperoxidase can alter the function of A549 human lung cancer cells. We observed that MPO promoted the proliferation of cancer cells and inhibited their apoptosis. Additionally, it increased the phosphorylation of AKT and ERK. MPO was rapidly bound to and internalized by A549 cells, retaining its enzymatic activity. Furthermore, MPO partially translocated into the nucleus and was detected in the chromatin-enriched fraction. Effects of MPO on cancer cell function could be reduced when MPO uptake was blocked with heparin or upon inhibition of the enzymatic activity with the MPO inhibitor 4-aminobenzoic acid hydrazide (4-ABAH). Lastly, we have shown that tumour-bearing mice treated with 4-ABAH had reduced tumour burden when compared to control mice. Our results highlight the role of MPO as a neutrophil-derived enzyme that can alter the function of lung cancer cells.

Original languageEnglish
Article number1587
Issue number8
Number of pages17
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023 by the authors.

    Research areas

  • A549 cells, apoptosis, myeloperoxidase (MPO), neutrophil, non-small-cell lung cancer (NSCLC), proliferation

ID: 369870329